PMID- 34350676
OWN - NLM
STAT- MEDLINE
DCOM- 20211101
LR  - 20211101
IS  - 1529-8019 (Electronic)
IS  - 1396-0296 (Linking)
VI  - 34
IP  - 5
DP  - 2021 Sep
TI  - Tanshinone IIA alleviates vitiligo by suppressing AKT mediated CD8(+)  T cells 
      activation in a mouse model.
PG  - e15086
LID - 10.1111/dth.15086 [doi]
AB  - Tanshinone IIA has been reported to exhibit anti-inflammatory effects, while it 
      is not clear whether Tanshinone IIA has protective role in vitiligo. 
      Premelanosome (PMEL) CD8(+) T cells were adoptive transferred into Krt14- Kitl* 
      mice with Kit ligand (KITL) over-expressed, to construct the vitiligo model. 
      Pdk1(fl/fl) and Stat3(fl/fl) mice were crossed with Cd8(cre) mice to establish 
      Pdk1(TKO) and Stat3(TKO) mice. Tanshinone IIA (200 mug) was intravenous injected 
      to treat vitiligo in mice every 3 days. The accumulation of macrophages and 
      CD8(+) T cells in the ear skin was assayed by flow cytometry. Bone marrow-derived 
      macrophages (BMDMs) were induced and stimulated with lipopolysaccharides (LPS) 
      and IL-4. It was found that Tanshinone IIA alleviated the development of 
      vitiligo, impaired PMEL CD8(+) T cells accumulation in the ear skin, and 
      inhibited LPS-induced TNF-alpha, IL-6, and IL-1beta expression and secretion in BMDMs, 
      which could also inhibit IL-4-induced Arg-1 and Mrc-1 expression in BMDMs. In 
      addition, Tanshinone IIA could inhibit the proliferation and cytotoxic function 
      of CD8(+) T cells indicated by the expression of Perforin, Granzymeb, and IFN-gamma. 
      Furthermore, Tanshinone IIA treated Pdk1(TKO) mice, not Stat3(TKO) mice, showed 
      impaired PMEL CD8(+) T cells accumulation in the ear skin. In summary, Tanshinone 
      IIA alleviates vitiligo development with impaired CD8(+) T cells accumulation and 
      activation of Pdk1-Akt pathway.
CI  - (c) 2021 Wiley Periodicals LLC.
FAU - Zhang, Diancai
AU  - Zhang D
AD  - Yidu Central Hospital of Weifang, Qingzhou, China.
FAU - Wang, Yujie
AU  - Wang Y
AD  - Yidu Central Hospital of Weifang, Qingzhou, China.
FAU - Li, Guangzhi
AU  - Li G
AD  - Yidu Central Hospital of Weifang, Qingzhou, China.
FAU - Zhang, Baoxiang
AU  - Zhang B
AUID- ORCID: 0000-0002-5453-5399
AD  - Yidu Central Hospital of Weifang, Qingzhou, China.
LA  - eng
PT  - Journal Article
DEP - 20210812
PL  - United States
TA  - Dermatol Ther
JT  - Dermatologic therapy
JID - 9700070
RN  - 0 (Abietanes)
RN  - 03UUH3J385 (tanshinone)
RN  - EC 2.7.11.1 (Proto-Oncogene Proteins c-akt)
SB  - IM
MH  - Abietanes/pharmacology
MH  - Animals
MH  - CD8-Positive T-Lymphocytes
MH  - Mice
MH  - Proto-Oncogene Proteins c-akt
MH  - *Vitiligo/drug therapy
OTO - NOTNLM
OT  - Akt
OT  - BMDMs
OT  - Pdk1
OT  - Tanshinone IIA
OT  - vitiligo
EDAT- 2021/08/06 06:00
MHDA- 2021/11/03 06:00
CRDT- 2021/08/05 06:49
PHST- 2020/12/07 00:00 [received]
PHST- 2021/08/02 00:00 [accepted]
PHST- 2021/08/06 06:00 [pubmed]
PHST- 2021/11/03 06:00 [medline]
PHST- 2021/08/05 06:49 [entrez]
AID - 10.1111/dth.15086 [doi]
PST - ppublish
SO  - Dermatol Ther. 2021 Sep;34(5):e15086. doi: 10.1111/dth.15086. Epub 2021 Aug 12.